These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26429605)

  • 1. Vancomycin Tissue Pharmacokinetics in Patients with Lower-Limb Infections via In Vivo Microdialysis.
    Housman ST; Bhalodi AA; Shepard A; Nugent J; Nicolau DP
    J Am Podiatr Med Assoc; 2015 Sep; 105(5):381-8. PubMed ID: 26429605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue pharmacokinetics of cefazolin in patients with lower limb infections.
    Bhalodi AA; Housman ST; Shepard A; Nugent J; Nicolau DP
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5679-83. PubMed ID: 24041887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.
    Hamada Y; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2016 Feb; 60(2):955-61. PubMed ID: 26621619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations.
    Frymoyer A; Guglielmo BJ; Wilson SD; Scarpace SB; Benet LZ; Hersh AL
    Pharmacotherapy; 2011 Sep; 31(9):871-6. PubMed ID: 21923588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
    Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
    Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
    Frymoyer A; Guglielmo BJ; Hersh AL
    Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
    Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
    Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections.
    Hamada Y; Kuti JL; Nicolau DP
    J Antimicrob Chemother; 2015 Jul; 70(7):2064-7. PubMed ID: 25802284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED; Herald M; Koura F
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia.
    Mizokami F; Shibasaki M; Yoshizue Y; Noro T; Mizuno T; Furuta K
    Clin Interv Aging; 2013; 8():1015-21. PubMed ID: 23966773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Clemens EC; Chan JD; Lynch JB; Dellit TH
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
    Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
    Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
    Placencia FX; Kong L; Weisman LE
    Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.